Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242687 | 0.88 | MAOA (0.59) | MAOBMAOANOTUMKDM4EALDH1A1 | |
| SCHEMBL5177372 | 0.82 | MAOB (0.83) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22803696 | 0.82 | NPC1 (0.67) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL8533952 | 0.81 | NPC1 (0.58) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL30795393 | 0.81 | MAOA (0.56) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL31668688 | 0.80 | MAOA (0.66) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL4347943 | 0.80 | NPC1 (0.69) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22803315 | 0.80 | MAOA (0.58) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL7038134 | 0.79 | MAOB (0.61) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL1576877 | 0.79 | NPC1 (0.63) | MAOBMAOANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAOB 1218/4885MAOA 779/4885NPC1 2032/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | MAOB 1211/4885MAOA 1449/4885NPC1 318/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAOB 1218/4885MAOA 779/4885NPC1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.